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Gonadotropin-releasing hormone analogs
for ovarian function protection during
chemotherapy in young early breast cancer
patients: the last piece of the puzzle?
In western countries, nearly 6% of women with newly diagnosed
breast cancer are younger than 40 years old [1]. This percentage
rises to 25% in developing countries [2]. At least half of young
women with breast cancer desire children after treatment [3].
Nevertheless, breast cancer patients have the lowest chances
among cancer survivors to subsequently become pregnant [4]. A
potential important cause of such a low pregnancy rate in breast
cancer survivors is represented by the possible gonadal damage
induced by anticancer systemic therapies [5]. At the time of treat-
ment decision-making,50% of young breast cancer patients are
concerned about the potential risk of developing chemotherapy-
induced premature ovarian failure (POF) and subsequent fertility
impairment [6]. Embryo or oocyte cryopreservation is considered
standard fertility preserving techniques but they cannot protect
gonadal function during chemotherapy [4, 7]. Temporary ovarian
suppression with gonadotropin-releasing hormone analogs
(GnRHa) during chemotherapy is another available option that
has been mainly investigated as a strategy to preserve ovarian
function during systemic cytotoxic therapy [5]. However, this
strategy has been widely debated in the last years with supporters
[8] and strong detractors [9] of its protective role.
The OPTION study, published in this issue of Annals of Oncology,
provides additional insights on the efficacy of GnRHa as a strategy
to preserve ovarian function during chemotherapy [10]. In this
phase III study, 227 premenopausal breast cancer patients were
randomized to receive adjuvant or neo-adjuvant chemotherapy
alone (control group) or with concurrent administration of the
GnRHa goserelin for the whole duration of systemic cytotoxic ther-
apy (experimental group). Primary analysis was carried out in 202
patients (89% of the population randomized in the study). The
study showed that concurrent use of GnRHa during chemotherapy
was associated with a reduced incidence of amenorrhea (defined as
no menses between 12 and 24 months after randomization), from
38.3% in the control group to 22.1% in the experimental group
(P¼ 0.015). The protective effect of the GnRHa goserelin was also
confirmed by the secondary analysis in which a composite endpoint
was used to define chemotherapy-induced POF, i.e. amenorrhea
and follicle-stimulating hormone values above 25 IU/l. This analysis
was conducted in 131 patients (58% of the population randomized
in the study): the incidence of chemotherapy-induced POF was
34.8% in the control group when compared with 18.5% in the ex-
perimental group (P¼ 0.048). The protective effect was more prom-
inent in patients aged40 years: in this subgroup of women, the
incidence of amenorrhea decreased from 25.4% to 10.0%
(P¼ 0.032) and the incidence of chemotherapy-induced POF from
20.0% to 2.6% (P¼ 0.038) when GnRHa was added to chemother-
apy. On the contrary, in patients older than 40 years the difference in
the incidence of both amenorrhea and chemotherapy-induced POF
between the control and experimental groups was not statistically
significant. Although no standard definition of chemotherapy-
induced POF exists so far, it has been recently proposed that anti-
Mullerian hormone (AMH), a reliable hallmark of ovarian reserve,
may become a biomarker of gonadotoxicity following the use of
anticancer systemic therapies [11, 12]. Secondary results from the
OPTION study showed a marked fall of AMH values after chemo-
therapy in both treatment arms with no difference between the con-
trol and experimental groups. Taking into account these findings,
the authors concluded that the amount of ovarian function
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preserved by the use of GnRHa may be relatively small. However,
the limited number of patients with available AMH values (109
women at 24 months, 48% of the population randomized in the
study) does limit the reliability of this analysis [10].
The results of the OPTION study showing a beneficial effect of
temporary ovarian suppression with GnRHa during chemotherapy
in preserving ovarian function are consistent with those of the
other largest studies that have recently investigated the efficacy of
this strategy in breast cancer patients [13–15]. Along the same
direction, our updated meta-analysis including 12 randomized
controlled trials that assessed the role of temporary ovarian sup-
pression with GnRHa during chemotherapy in 1231 premeno-
pausal breast cancer patients confirmed the protective effective of
this strategy [16]. We observed that the concurrent use of GnRHa
during chemotherapy was associated with more than 60% reduc-
tion in the risk of developing chemotherapy-induced POF (odds
ratio [OR] 0.36, 95% confidence intervals [CI] 0.23–0.57,
P< 0.001) [16]. If the results of the largest phase III studies, includ-
ing those of the OPTION trial as well as the findings of our meta-
analysis, consistently show the beneficial effect of temporary ovar-
ian suppression with GnRHa during chemotherapy in ovarian
function protection, why is its role still debated? Skepticism about
this strategy primarily relies on the fact that the main outcome
investigated in all the trials was not represented by long-term preg-
nancy rate but resumption of menses that may not be a good surro-
gate of fertility restoration. Nevertheless, including data coming
from the recent largest studies [14, 15], our meta-analysis showed
a higher pregnancy rate in women treated with GnRHa than
in those who received chemotherapy alone (OR 1.83, 95% CI
1.02–3.28, P¼ 0.041) [16]. Therefore, although the numbers re-
main relatively small (33 vs. 19 women with a subsequent preg-
nancy), these data suggest the possible additional role of
temporary ovarian suppression with GnRHa during chemotherapy
as a strategy not only for ovarian function protection but also for
fertility preservation. Although the difference was not statistically
significant, more pregnancies were observed in patients receiving
GnRHa when compared with those treated with chemotherapy
alone also in the OPTION study (9 vs. 6 pregnancies) [10].
On the basis of the growing amount of evidence on the protect-
ive role of temporary ovarian suppression with GnRHa during
chemotherapy, several guidelines have been recently updated to
acknowledge the possibility of discussing this strategy with young
breast cancer patients interested in preserving fertility and/or
ovarian function [17–20]. The results of the OPTION study fur-
ther strengthen this recommendation. Embryo or oocyte cryo-
preservation remains the first strategies to be proposed in
patients willing to preserve fertility before starting anticancer sys-
temic therapies. Temporary ovarian suppression with GnRHa
during chemotherapy should now be considered another stand-
ard option that is not an alternative nor mutually exclusive with
the surgical strategies. With the results of the OPTION study, has
the puzzle on the protective role of temporary ovarian suppres-
sion with GnRHa during chemotherapy been completed? We be-
lieve that the answer should be ‘yes’. Nevertheless, an individual
patient-data meta-analysis of randomized controlled trials inves-
tigating the role of temporary ovarian suppression with GnRHa
during chemotherapy in breast cancer patients is currently on-
going (PROSPERO registration number: CRD42014015638) [5].
Final results of this meta-analysis, expected for the end of 2017,
are awaited to better identify those patients who are more likely
to benefit from the use of this strategy.
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Whose side are you on?
Data on the prognostic and predictive values of primary tumor
sidedness in metastatic colorectal cancer (mCRC) patients have,
over the last year or so, been reported at oncology meetings and,
in some cases, published subsequently as full articles. The present
edition of Annals of Oncology includes two major articles, one on
the impact of tumor sidedness in three panitumumab trials [1]
and the other a meta-analysis of published and unpublished data
from randomized controlled trials, comparing chemotherapy
plus anti-epidermal growth factor receptors (EGFRs) with
chemotherapy alone or combined with bevacizumab [2]. The
vast majority of these trials deal with treatment-naive RAS wild-
type mCRC patients, except for one in the meta-analysis which is
testing chemotherapy plus or minus panitumumab in a second-
line setting.
The German AIO Group was the first to address the question
of the prognostic and predictive value of primary tumor sided-
ness using recent treatment schedules, and reported initial find-
ings from the AIO KRK 0306 (FIRE-3) trial of first-line treatment
with FOLFIRI in combination with cetuximab or bevacizumab
[3]. Data from an analysis of FIRE-3 and CRYSTAL (a trial testing
chemotherapy plus or minus cetuximab) have been then analyzed
together and recently published [4]. The results published in this
issue of Annals of Oncology, essentially mirror those of these pre-
vious works with cetuximab and therefore greatly strengthen the
initially suggested prognostic and predictive values of primary
tumor sidedness.
The first important result from these studies is that sidedness,
which has for decades been recognized as a significant prognostic
factor in mCRC [5], is still an important and clinically relevant
prognostic factor in 2017 in the era of doublet chemotherapy
associated with a targeted agent. Why patients with proximal
tumors fare worse than those with distal tumors remains unclear.
One may argue that it is because patients with proximal tumors
are generally older, that the tumor is more often poorly differenti-
ated, and that the primary tumor is less often removed in these
patients. At the molecular level, BRAF mutations, the CpG island
methylator phenotype (CIMPþ), and the deficient mismatch
repair phenotype (dMMR), which are known to be indicative of a
poor prognosis in metastatic patients, are more often present in
proximal tumors [6]. But multivariate analyses have shown that,
even when adjusted for some of these factors [1], tumor sidedness
remains prognostic, suggesting that these factors may only in part
explain the poor prognosis of proximal tumors. Even if it seems a
bit disappointing, at the time of consensual worldwide molecular
classifications in CRC patients [7], we have to admit that tumor
location and anatomy are relevant and may yield prognostic in-
formation in our daily practice, where molecular assessments are
not always performed. So, tumor location and anatomy should
henceforth be taken into account as a stratification factor for all
future clinical trials in mCRC and in the years ahead, we will have
to identify the “still unknown” factors that confer such a poor
prognosis on proximal tumors.
The second important result is that proximal and distal tumors
do not seem to respond in the same way to anti-EGFR and anti-
vascular endothelial growth factor (VEGF) therapies. Current
knowledge, enhanced by these two articles, suggests that first-line
anti-EGFRs should be considered for distal mCRC and that anti-
VEGF therapy may be more appropriate for proximal colon can-
cers. However, whereas the results are significant and quite robust
for distal tumors and their excellent outcome with first-line anti-
EGFRs, the results for proximal tumors are far less clear to date.
This is due, at least in part, to the lower number of proximal
tumors (one-third of the whole population), which limits statis-
tical power and hence the ability to show any significant differ-
ences and also the reliability of other findings. For example,
objective response rates remain in favor of anti-EGFRs even in
the proximal tumor group and in trials with chemotherapy plus
bevacizumab as the control arm, suggesting that at least some pa-
tients with proximal tumors may still benefit from anti-EGFRs.
This suggests that rather than anti-EGFRs being ineffective in
proximal tumor patients, the optimal treatment sequence in a
continuum of care for these patients should not start with anti-
EGFRs in most cases. As proximal tumors have a poor prognosis
and are potentially more resistant to anti-EGFRs, a trial is prob-
ably needed to assess aggressive first-line treatment with a triplet
chemotherapeutic regimenþ/ a targeted agent, in patients
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